50 | Chapter 2 181. Ochodnicka-Mackovicova, K. et al. NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity. Blood 126, 1324–1335 (2015). 182. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160–1166 (2007). 183. Lee, J.-H. & Paull, T. T. ATM activation by DNA double-strand breaks through the Mre11Rad50-Nbs1 complex. Science 308, 551–554 (2005). 184. Stracker, T. H. & Petrini, J. H. J. The MRE11 complex: starting from the ends. Nat. Rev. Mol. Cell Biol. 12, 90–103 (2011). 185. Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol. Cell 66, 801–817 (2017). 186. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. & Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14, 289–300 (2000). 187. Zannini, L., Delia, D. & Buscemi, G. CHK2 kinase in the DNA damage response and beyond. J. Mol. Cell Biol. 6, 442–457 (2014). 188. Stevens, C., Smith, L. & La Thangue, N. B. Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 5, 401–409 (2003). 189. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816 (1993). 190. Bredemeyer, A. L. et al. DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature 456, 819–823 (2008). 191. Steinel, N. C. et al. The ataxia telangiectasia mutated kinase controls Igκ allelic exclusion by inhibiting secondary Vκ-to-Jκ rearrangements. J. Exp. Med. 210, 233–239 (2013). 192. Kinner, A., Wu, W., Staudt, C. & Iliakis, G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678–5694 (2008). 193. Woo, J. S., Alberti, M. O. & Tirado, C. A. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp. Hematol. Oncol. 3, 16 (2014). 194. Chernoff, J. The two-hit theory hits 50. Mol. Biol. Cell 32, rt1 (2021). 195. Shurtleff, S. A. et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9, 1985–1989 (1995). 196. Angione, S. D. A. et al. Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy. J. Pediatr. Pharmacol. Ther. JPPT Off. J. PPAG 26, 541–555 (2021). 197. Schäfer, D. et al. Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood vol. 131 821–826 (2018). 198. Kantner, H.-P. et al. ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. Neoplasia 15, 1292–1300 (2013). 199. Ziech, D., Franco, R., Pappa, A. & Panayiotidis, M. I. Reactive oxygen species (ROS)- -induced genetic and epigenetic alterations in human carcinogenesis. Mutat. Res. 711, 167–173 (2011). 200. Kuiper, R. P. & Waanders, E. A RAG driver on the road to pediatric ALL. Nat. Genet. 46, 96–98 (2014). 201. Paulsson, K. et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat. Genet. 47, 672–676 (2015). 202. Aricò, M. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342, 998–1006 (2000).
RkJQdWJsaXNoZXIy MTk4NDMw